BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

BIOGEN INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$233.48+0.83 (+0.36%)

Close on Oct 19, 2026

Market cap: $34.72B
P/E (TTM): 41.3
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$9.89BFY2025, +4.9% a year since FY2011

Where these numbers come from

Parsed from the XBRL in Biogen's annual and quarterly filings with the SEC
Per-share figures adjusted for the 3-for-1 split on Jan 18, 2001
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BIIB.

Revenue growth0.3% · median 9.1%

Gross margin74.0% · median 74.6%

Net margin8.3% · median 20.9%

Company	Revenue	Growth
AMGN	$38.10B	+9.1%
GILD	$30.46B	+5.5%
REGN	$15.53B	+9.3%
BIIB	$10.03B	+0.3%
NBIX	$3.37B	+34.4%
MRNA	$2.23B	-27.6%

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 7,500
Held by institutions: 96.3%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 875045

Advertisement
300 × 250